Core Viewpoint - Aoxing Life Science Technology (06118.HK) expects to record a profit attributable to shareholders of no less than RMB 30 million for the fiscal year ending December 31, 2025, compared to an estimated profit of approximately RMB 16 million for the fiscal year ending December 31, 2024 [1][1]. Financial Performance - The profit growth is primarily attributed to the company's focus on strategic efficiency measures, particularly the optimization of administrative management and research and development expenses, leading to a decrease in operating expenses [1][1]. - There is an increase in other income, mainly driven by foreign exchange gains recorded for the fiscal year ending December 31, 2025 [1][1]. - Financial costs have decreased, contributing to the overall profit growth [1][1].
【盈喜】奥星生命科技(06118.HK)料年度股东应占溢利不少于3000万元